Gene-based blood test for melanoma spread evaluates treatment progress

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in late stages of melanoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login